This episode of DeviceTalks AI offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of DeviceTalks AI, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to DeviceTalks AI on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/

Thank you for supporting DeviceTalks AI!

Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

DeviceTalks

Related tracks